CDK1 and neoplasm: The trial has also evaluated the MK-1775 effects on pY15-Cdk1 (reduction in two of five paired tumor tissue biopsies) and on DNA damage markers (increase in γH2AX levels in three of five tumor tissue paired biopsies).